Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colestipol for Teriflunomide Elimination
NCT02263547Phase 1Terminated
- Start
- Mar 2015
- Primary completion
- Jun 2016
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of colestipol in multiple sclerosis (MS). Primary endpoint: Teriflunomide Concentrations at Day 28. Started Mar 2015; status: terminated.
02
Drugs
colestipol
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02263547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02263547.